MedTrace Logo

Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer

NCT00133913 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 486

Last updated 2008-03-19

No results posted yet for this study

Summary

This study enrolled patients with measurable metastatic colorectal cancer. Blood was drawn prior to the patient receiving a new therapy for his/her cancer and subsequently at 7-14 days, 3-4 weeks, and when an imaging study was done (\~every 6 to 12 weeks). The blood was tested to find circulating tumor cells (CTCs) and to count them. The CTC levels were compared to the imaging study results to see if the CTC number and the imaging result (progression/no progression) were in agreement. Maximum active study participation was 12 months with up to 8 blood draws being taken. All patients are currently being followed for up to 24 months from their off study date for survival. The CTC result will also be used to see if there is a difference in survival and progression-free survival for those patients with and without a certain number of CTCs.

Conditions

Interventions

PROCEDURE

Phlebotomy

Peripheral blood draws for testing of circulating tumor cells

Sponsors & Collaborators

  • Immunicon

    lead INDUSTRY

Principal Investigators

  • Steven Cohen, MD · Fox Chase Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2007-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00133913 on ClinicalTrials.gov